Stocks · News reference

Bolt Biotherapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.

Aug 12, 2026, 3:17 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 11, 2026, 8:20 PMBenzinga Newsdesk
Bolt Biotherapeutics Q2 EPS $(4.57) Misses $(2.88) Estimate, Sales $5.000K Miss $500.000K Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.57) per share which missed the analyst consensus estimate of $(2.88) by 58.68 percent. This is a 2.47 percent decrease over losses of $(4.46) per share
Read original at benzinga
BOLT
BenzingaMay 29, 2026, 12:33 PMBenzinga Newsdesk
Rodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Price Target of $22.
Read original at benzinga
BOLT